A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Phase 1/2 Unknown
260 enrolled
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Phase 1/2 Unknown
120 enrolled
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
Phase 1/2 Unknown
324 enrolled
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Phase 1/2 Unknown
72 enrolled
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
Phase 1/2 Unknown
75 enrolled
Vaccination With Flt3L, Radiation, and Poly-ICLC
Phase 1/2 Unknown
56 enrolled
CINDERELLA
Phase 1/2 Unknown
44 enrolled
IMX-110 in Patients With Advanced Solid Tumors
Phase 1/2 Unknown
70 enrolled
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Phase 1/2 Unknown
116 enrolled
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Phase 1/2 Unknown
314 enrolled
Study of TFX06 in Women With Advanced Breast Cancer.
Phase 1/2 Unknown
74 enrolled
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Phase 1/2 Unknown
125 enrolled
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Phase 1/2 Unknown
40 enrolled
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Phase 1/2 Unknown
87 enrolled
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Phase 1/2 Unknown
45 enrolled
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Phase 1/2 Unknown
300 enrolled
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
Phase 1/2 Unknown
65 enrolled
PLEASURABLE
Phase 1/2 Unknown
59 enrolled
REGOMUNE
Phase 1/2 Unknown
747 enrolled
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
Phase 1/2 Unknown
40 enrolled
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Phase 1/2 Unknown
102 enrolled
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases
Phase 1/2 Unknown
39 enrolled
68Ga PET/CT Imaging in Breast Cancer Patients
Phase 1/2 Unknown
50 enrolled
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
Phase 1/2 Unknown
233 enrolled
FUTURE
Phase 1/2 Unknown
140 enrolled
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Phase 1/2 Unknown
95 enrolled
ImmunoBreast - A Phase Ib Study
Phase 1/2 Unknown
20 enrolled
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
Phase 1/2 Unknown
170 enrolled
ENZENO
Phase 1/2 Unknown
106 enrolled
METROmaJX
Phase 1/2 Unknown
197 enrolled
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
Phase 1/2 Unknown
24 enrolled
KORNELIA
Phase 1/2 Unknown
90 enrolled
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Phase 1/2 Unknown
132 enrolled
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Phase 1/2 Unknown
31 enrolled
Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c
Phase 1/2 Unknown
78 enrolled
Multi-4SCAR-T Therapy Targeting Breast Cancer
Phase 1/2 Unknown
100 enrolled
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
Phase 1/2 Unknown
100 enrolled
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
Phase 1/2 Unknown
60 enrolled
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Phase 1/2 Unknown
42 enrolled
TORCMEK
Phase 1/2 Unknown
118 enrolled
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Phase 1/2 Unknown
40 enrolled
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Phase 1/2 Unknown
39 enrolled
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
Phase 1/2 Unknown
20 enrolled
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
Phase 1/2 Unknown
67 enrolled
Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
Phase 1/2 Unknown
40 enrolled
Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells
Phase 1/2 Unknown
200 enrolled
Circadian Thermal Sensing to Detect Breast Disease
Phase 1/2 Unknown
173 enrolled
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Phase 1/2 Unknown
128 enrolled
Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer
Phase 1/2 Unknown
30 enrolled
Tissue Stresses of Cancer (Force Horizon 2020)
Phase 1/2 Unknown
200 enrolled